Table 2.
Risk factors for DCGF in the study cohort
| aAdjusted HR (95% CI) | P | |
|---|---|---|
| Age (years) | 1.00 (0.97–1.02) | 0.71 |
| Male sex (.vs female) | 2.50 (1.46–4.28) | < 0.001 |
| Duration from transplant to allograft IgAN diagnosis (years) | 1.05 (0.98–1.12) | 0.18 |
| eGFR (.vs ≥ 60 mL/min/1.73 m2) | ||
| ≥ 45 and < 60 | 1.61 (0.68–3.82) | 0.28 |
| ≥ 30 and < 45 | 2.35 (1.02–5.38) | 0.04 |
| ≥ 15 and < 30 | 6.88 (2.94–16.14) | < 0.001 |
| < 15 | 7.43 (2.28–24.17) | < 0.001 |
| Albuminuria (.vs none or trace) | ||
| 1+ at baseline | 0.95 (0.43–2.10) | 0.90 |
| ≥ 2+ at baseline | 1.56 (0.86–2.83) | 0.15 |
| 1+ at 6 months | 1.81 (0.82–3.98) | 0.14 |
| ≥ 2+ at 6 months | 5.64 (3.20–9.93) | < 0.001 |
| MAP (mmHg) | ||
| High MAP (> 100 mmHg) at baseline | 1.12 (0.67–1.90) | 0.66 |
| High MAP (> 100 mmHg) at 6 months | 1.13 (0.72–1.77) | 0.59 |
| Coexisting acute rejection | 1.07 (0.65–1.76) | 0.80 |
| Oxford classification | ||
| M1 (vs. M0) | 1.09 (0.59–2.03) | 0.78 |
| E1 (vs. E0) | 1.62 (0.89–2.98) | 0.11 |
| S1 (vs. S0) | 1.36 (0.49–3.80) | 0.52 |
| T1 or T2 (vs. T0) | 2.08 (1.21–3.55) | 0.008 |
| C1 or C2 (vs. C0) | 1.50 (0.88–2.54) | 0.13 |
DCGF Death-censored-graft failure, IgAN Immunoglobulin A nephropathy, eGFR Estimated glomerular filtration rate, MAP Mean arterial pressure
aAdjusted with all variables in the table. When albuminuria or MAP after 6 months were included in the model, the values of eGFR, MAP, and the degree of albuminuria at 6 months from diagnosis were included instead the baseline values. Missing values were imputed using the multivariate imputation using classification and the regression trees method